Nordx

Nordx was paid $21.75M by Medicaid between Jan 2018 and Dec 2024, across 257 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 31% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Maine

Rank by total paid#1 of 10

Median peer was paid$404K

This provider vs. median54×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	228,462	$1.46M
2019	239,515	$1.99M
2020	242,879	$3.24M
2021	355,008	$6.55M
2022	300,991	$3.93M
2023	258,562	$2.44M
2024incomplete	236,275	$2.13M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	31%	121,101	103,447	$6.69M
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	6.7%	24,293	18,617	$1.47M
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	5.5%	86,434	73,761	$1.19M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	4.4%	28,811	21,976	$953K
84443	Thyroid stimulating hormone (TSH)	4.0%	82,029	78,097	$863K
80053	Comprehensive metabolic panel	3.8%	135,058	121,468	$825K
80061	Lipid panel	2.7%	72,930	69,577	$594K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	2.6%	31,392	30,051	$564K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	2.4%	116,398	101,340	$523K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	1.6%	19,380	18,393	$344K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	1.6%	15,470	14,727	$340K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	1.6%	15,443	14,702	$340K

245 more codes

83036	Hemoglobin; glycosylated (A1C)	1.4%	53,946	$295K
36415	Collection of venous blood by venipuncture	1.0%	199,759	$219K
87481		<1%	9,970	$202K
87522	Neg quan hep c or qual rna	<1%	5,871	$201K
86803		<1%	20,983	$192K
82728		<1%	20,677	$190K
82607		<1%	20,595	$175K
80048	Basic metabolic panel (calcium, ionized)	<1%	52,454	$152K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	4,006	$151K
86003		<1%	2,838	$149K
86780		<1%	13,404	$143K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	6,607	$136K
87511		<1%	6,494	$134K
85027		<1%	40,053	$133K
82746		<1%	14,549	$130K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	1,642	$130K
84439		<1%	20,346	$129K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	6,547	$128K
87536		<1%	3,120	$127K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	4,915	$126K
87340		<1%	15,481	$125K
86706		<1%	13,328	$118K
83550		<1%	19,693	$111K
86704		<1%	11,502	$108K
84403		<1%	6,456	$108K
86480		<1%	3,131	$101K
87086	Culture, bacterial; quantitative colony count, urine	<1%	23,913	$101K
88142		<1%	5,527	$98K
83970		<1%	4,605	$91K
86481		<1%	2,180	$91K
83540		<1%	20,691	$86K
87902		<1%	1,110	$79K
83655		<1%	6,713	$77K
87070		<1%	10,750	$70K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	2,800	$68K
83735		<1%	24,555	$67K
82670		<1%	2,889	$64K
84153		<1%	5,362	$64K
86618		<1%	5,900	$62K
86762		<1%	5,018	$58K
84702		<1%	4,808	$58K
86787		<1%	5,238	$56K
82784		<1%	6,490	$54K
83001		<1%	3,422	$51K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	1,843	$48K
87186		<1%	10,669	$47K
86140		<1%	13,713	$46K
83880		<1%	3,943	$45K
88175	Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer	<1%	1,928	$44K
84146		<1%	2,850	$43K
80074		<1%	1,227	$42K
85610		<1%	27,372	$41K
86038		<1%	4,532	$39K
84402		<1%	2,313	$33K
82043		<1%	10,997	$32K
87077		<1%	11,221	$32K
86235		<1%	907	$31K
83516		<1%	3,672	$31K
87517		<1%	1,034	$31K
82785		<1%	2,307	$31K
83002		<1%	1,945	$30K
81220	CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants	<1%	375	$28K
80076		<1%	5,309	$25K
84480		<1%	2,389	$24K
87209		<1%	1,704	$23K
86765		<1%	2,141	$23K
86735		<1%	2,110	$23K
84481		<1%	1,960	$22K
86617		<1%	926	$21K
86850		<1%	6,680	$21K
82274		<1%	2,426	$21K
85652		<1%	11,666	$21K
86800		<1%	1,868	$20K
87493		<1%	1,659	$20K
81001		<1%	13,834	$20K
86376		<1%	1,673	$20K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	454	$19K
80164		<1%	3,824	$19K
G0328	Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous	<1%	2,687	$19K
82533		<1%	1,570	$18K
83690		<1%	4,106	$18K
87046		<1%	1,078	$18K
83020		<1%	1,721	$18K
86334		<1%	2,167	$17K
84165		<1%	3,302	$17K
82105		<1%	1,471	$17K
84100		<1%	6,942	$17K
87338		<1%	1,889	$17K
86160		<1%	1,126	$16K
86364		<1%	2,203	$16K
86708		<1%	1,725	$16K
83721		<1%	2,776	$16K
86900		<1%	6,661	$15K
86360		<1%	1,543	$15K
86901		<1%	6,648	$15K
81511		<1%	158	$15K
82570		<1%	5,399	$14K
82950		<1%	3,237	$14K
86431		<1%	3,430	$14K
83993		<1%	870	$13K
86359		<1%	1,550	$13K
86200		<1%	1,394	$12K
80197		<1%	4,701	$12K
84305		<1%	760	$12K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	515	$12K
87205		<1%	4,144	$11K
86696		<1%	729	$10K
83883		<1%	1,160	$10K
84460		<1%	3,196	$10K
84156		<1%	5,373	$10K
83615		<1%	2,706	$10K
82977		<1%	1,776	$9K
83010		<1%	1,048	$9K
80050	General health panel	<1%	715	$9K
87177		<1%	1,347	$9K
80069		<1%	2,735	$9K
82150		<1%	2,180	$9K
84425		<1%	813	$9K
82550		<1%	2,448	$9K
84550		<1%	3,773	$9K
80178		<1%	2,504	$8K
80175		<1%	1,678	$8K
86665		<1%	669	$8K
87427		<1%	1,057	$8K
83921		<1%	840	$8K
81003		<1%	6,734	$8K
87799		<1%	623	$8K
83520		<1%	754	$7K
85730		<1%	1,752	$7K
86695		<1%	730	$7K
82248		<1%	2,222	$7K
86682		<1%	570	$7K
87045		<1%	1,080	$7K
85045		<1%	2,293	$6K
83525		<1%	662	$6K
86225		<1%	599	$6K
84450		<1%	1,893	$5K
82103		<1%	561	$5K
80159		<1%	1,377	$5K
80177		<1%	1,310	$5K
86663		<1%	444	$5K
82947		<1%	1,950	$5K
82652		<1%	202	$5K
88184		<1%	157	$4K
86664		<1%	348	$4K
84155		<1%	2,691	$4K
82565		<1%	2,079	$4K
0202U	Oncology (prostate), multianalyte, gene expression profiling	<1%	20	$4K
84436		<1%	1,084	$4K
82040		<1%	2,975	$4K
83519		<1%	268	$4K
86709		<1%	392	$4K
86039		<1%	442	$4K
85018		<1%	2,444	$4K
87634		<1%	131	$3K
84144		<1%	219	$3K
82247		<1%	1,050	$3K
G0472	Hepatitis c antibody screening, for individual at high risk and other covered indication(s)	<1%	709	$3K
84134		<1%	335	$3K
83021		<1%	152	$2K
82951		<1%	222	$2K
82310		<1%	938	$2K
86769		<1%	186	$2K
85007		<1%	1,236	$2K
85651		<1%	1,068	$2K
83521		<1%	188	$2K
86694		<1%	173	$2K
82627		<1%	172	$2K
87529		<1%	93	$2K
86308		<1%	424	$2K
87420		<1%	239	$2K
86304		<1%	145	$2K
85014		<1%	1,465	$2K
85660		<1%	339	$2K
87497		<1%	85	$1K
86677		<1%	140	$1K
81420	Fetal chromosomal aneuploidy genomic sequence analysis panel	<1%	626	$1K
84432		<1%	151	$1K
80156		<1%	237	$1K
82024		<1%	51	$1K
81000		<1%	715	$1K
84466		<1%	153	$1K
87329		<1%	130	$1K
P9603	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled	<1%	48,633	$1K
85732		<1%	196	$1K
84520		<1%	760	$1K
85613		<1%	133	$934.20
84075		<1%	468	$909.34
86147		<1%	25	$885.15
86146		<1%	42	$852.87
86807		<1%	17	$808.83
85379		<1%	102	$779.04
84132		<1%	457	$742.33
87040		<1%	88	$675.67
86335		<1%	42	$658.64
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	58	$655.76
82330		<1%	98	$639.12
88346		<1%	14	$627.16
80185		<1%	215	$626.31
87075		<1%	111	$596.00
81508		<1%	60	$594.19
84681		<1%	54	$576.74
86036		<1%	57	$561.85
84163		<1%	40	$556.85
84703		<1%	88	$508.67
84166		<1%	52	$488.83
86255		<1%	55	$480.90
84295		<1%	270	$439.09
86141		<1%	68	$351.94
82374		<1%	221	$351.38
82435		<1%	223	$333.40
87468		<1%	1,033	$290.95
84285		<1%	28	$268.71
G0145	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision	<1%	38	$267.66
86705		<1%	26	$250.63
87469		<1%	1,030	$250.59
82952		<1%	104	$250.43
87207		<1%	41	$239.60
82985		<1%	31	$231.15
86870		<1%	18	$229.36
87206		<1%	87	$219.15
84270		<1%	13	$218.57
G0123	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision	<1%	402	$203.61
82378		<1%	13	$192.27
81329		<1%	584	$191.80
80051		<1%	58	$148.33
84630		<1%	14	$148.07
80184		<1%	28	$125.00
84590		<1%	14	$115.83
80299		<1%	15	$111.92
86592		<1%	26	$89.67
86015		<1%	14	$82.13
80162		<1%	71	$66.22
86593		<1%	13	$44.00
86021		<1%	14	$42.55
99001		<1%	2,381	$41.12
87081		<1%	15	$35.84
87505		<1%	28	$35.20
81002		<1%	20	$26.83
G0103	Prostate cancer screening; prostate specific antigen test (psa)	<1%	1,671	$17.57
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	<1%	5,545	$4.10
G0499	Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result	0%	124	$0.00
80359		0%	13	$0.00
87484		0%	24	$0.00
80324		0%	13	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialSCHOFIELD, WILLIAM (PRESIDENT)